Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 1

Conditions

Burkitt Lymphoma 2Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (Ph+ALL) 1Oligodendroglioma 1Neurocytoma 1Lymphoma, T-Cell 1Lymphoma, Non-Hodgkin 1Lymphoma, Large-Cell, Anaplastic 1Lymphoma, Large B-Cell, Diffuse 1Lymphoma, B-Cell 1Lymphoma 1Hematologic Diseases 1Glioma 1Glioblastoma 1Ganglioneuroma 1Ganglioglioma 1Astrocytoma 1

Interventions

trametinib 1sacituzumab govitecan 1dabrafenib 1Vincristine 1TIC10 compound 1Carboplatin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has announcements × Glioblastoma × Vincristine × Clear all
NCT02684058 2023-12-13

Study of Efficacy and Safety of Dabrafenib in Combination With Trametinib in Pediatric Patients With BRAF V600 Mutation Positive LGG or Relapsed or Refractory HGG Tumors

Novartis

Phase 2 Completed
151 enrolled 45 charts 1 FDA
CNS

Astrocytoma, Ganglioneuroma, Glioblastoma, Glioma, Oligodendroglioma, Ganglioglioma, Neurocytoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡